We are pleased to share that our latest research article,
“Development of a tumor-region-selective activation monoclonal antibody targeting the 4-1BB receptor for enhanced therapeutic efficacy and safety,”
has been officially published in the International Journal of Biological Macromolecules.
This study presents a proof-of-concept monoclonal antibody that can be selectively activated within the tumor microenvironment to precisely engage the 4-1BB immune co-stimulatory receptor. By restricting activation to tumor regions, the approach achieves strong anti-tumor responses while reducing systemic toxicity—an innovation that embodies the core mechanism of PrecisemAb’s Antibody Lock technology platform.
We extend our warm congratulations to co-first authors Tzu-Yi Liao and Yen-Ling Liu, as well as to corresponding authors Kai Wen HO, Ph.D., and the late Tian-Lu Cheng, Ph.D.
It is a great honor to see this publication become part of Professor Cheng’s enduring scientific legacy.
PrecisemAb sincerely thanks all collaborating teams and supporting organizations involved in this project. We are proud to have contributed to the development of next-generation immunotherapies through innovative tumor-selective antibody engineering.
This publication reaffirms our commitment to creating safer, smarter, and more effective precision antibody therapeutics.
We will continue advancing technologies that unlock the future of antibody-based treatments.
